Syncromune announced the appointment of Stephen P. Dale, M.D., as Chief Medical Officer on January 6, 2026.135
Dr. Dale has over 20 years of global oncology R&D experience, previously serving as Head of R&D and CMO at Kura Oncology, and in senior roles at Kyowa Kirin and AstraZeneca.14
He will lead clinical development of SYNC-T, an in situ immunotherapy platform for solid tumors, including Phase 2 progression of SV-102.15
Syncromune is a clinical-stage biopharmaceutical company focused on SYNC-T for solid tumor cancers.15
Quotes from leadership highlight Dr. Dale's expertise in advancing therapies and prioritizing patient safety and impact.1
Sources:
1. https://www.biospace.com/press-releases/syncromune-continues-to-strengthen-executive-and-clinical-leadership-with-appointment-of-dr-stephen-p-dale-m-d-as-chief-medical-officer
3. https://firstwordpharma.com/river/type/People%20News
4. https://www.thepharmaletter.com/biotechnology/former-kura-oncology-cmo-stephen-dale-joins-syncromune